How to Source Japanese Pharmaceuticals Overseas: A Complete Guide for Healthcare Procurement

Why Japanese Pharmaceuticals Are in Demand Globally

Japan operates the world’s third-largest pharmaceutical market, with a domestic drug approval pipeline maintained by the Pharmaceuticals and Medical Devices Agency (PMDA). The breadth of Japan’s approved product base—spanning ethical medicines, biologics, and orphan-designated compounds—means that Japanese-origin pharmaceuticals are increasingly sought by healthcare institutions in markets where certain products are unavailable, unlicensed, or in short supply.

Several factors drive international procurement interest in Japanese pharmaceuticals:

• Unique approvals: Japan has approved certain compounds not yet licensed in Europe, the UK, Australia, or Southeast Asia. These products are legally accessible to overseas healthcare institutions through established importation frameworks.
• Manufacturing quality: Japan is a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S), meaning Japanese manufacturers operate under GMP standards recognised by regulatory authorities in over 50 countries.
• Supply reliability: For products where Japan is the primary or sole manufacturing base, Japanese exporters offer a direct route to stable supply.
• Regulatory asymmetry: Some medicines are standard approved products in Japan but carry orphan drug designation in the UK, EU, or US. This creates sourcing opportunities for rare disease treatment centres worldwide.

What Types of Products Can Be Sourced from Japan?

The Japanese approved product database includes a wide range of ethical medicines available for international export. Key categories include:

• Prescription pharmaceuticals (ethical medicines): The largest category, covering cardiovascular, neurological, oncology, endocrine, dermatological, and infectious disease indications.
• Orphan-designated medicines: Japan’s Ministry of Health, Labour and Welfare (MHLW) maintains a list of orphan drug designations. Many of these products are available for export to countries where they are needed for rare disease management.
• Ophthalmic preparations: Japan has a particularly strong pipeline of eye drops, surgical adjuncts, and ophthalmic ointments used by hospitals and specialist clinics internationally.
• Biologics and injectables: Including certain monoclonal antibodies, immunoglobulins, and enzyme replacement therapies approved in Japan.

Legal Frameworks for Overseas Procurement of Japanese Medicines

The legal basis for importing Japanese pharmaceuticals varies by destination country. Key frameworks include:

United Kingdom

The Human Medicines Regulations 2012 (Regulation 167) permits importation of unlicensed medicines as “Specials” when no licensed UK alternative is available. MHRA notification is required 28 days prior to first importation. The importer must hold a WDA(H) or Specials Manufacturing Authorisation.

Australia

The Therapeutic Goods Administration (TGA) operates the Special Access Scheme (SAS) and Authorised Prescriber framework. Japanese pharmaceuticals may be imported under SAS Category B or C for specific patient needs.

Singapore

The Health Sciences Authority (HSA) permits importation of unregistered medicines for specific clinical purposes under the Therapeutic Products Regulations. Singapore’s position as a regional pharmaceutical hub means that procurement teams frequently source directly from Japan-based exporters.

Other markets

Most regulated markets have an equivalent mechanism for accessing medicines not locally registered. Key requirements typically include a clinical justification, licensed importer, GMP documentation from the manufacturer, and GDP-compliant logistics.

The Role of a Japan-Based Pharmaceutical Exporter

Working with a specialist Japan-based pharmaceutical exporter simplifies international procurement significantly. A qualified exporter should be able to provide:

• Product sourcing across Japan’s approved ethical medicine base
• Certificate of Origin (CoO) confirming Japanese manufacture
• Patient Information Leaflet (PIL) and Summary of Product Characteristics documentation
• Certificate of Analysis (CoA) for batch-level quality confirmation
• GDP-compliant logistics, including cold chain packaging and temperature data loggers
• Ex Works pricing in major currencies (USD, EUR, JPY)
• Proforma Invoice and export documentation for customs clearance

How to Search for Japanese Pharmaceuticals: J-Lex Database

J-Lex (db.tasakipharma.com) is an English-language database of Japanese approved ethical medicines operated by TASAKI PHARMA. It allows international procurement teams to:

• Search by active ingredient, brand name, or manufacturer
• Confirm product formulation, packaging, and manufacturer details
• Submit product enquiries directly to TASAKI PHARMA

J-Lex covers a broad range of Japan-approved ethical medicines and is updated regularly. It is designed to serve international hospital pharmacists, procurement managers, and specialist clinicians who require access to Japan-sourced pharmaceutical products.

Standard Procurement Process with TASAKI PHARMA

1. Search J-Lex for the product of interest at db.tasakipharma.com
2. Submit an enquiry including your organisation’s pharmaceutical licence details and required quantity
3. Receive a quotation on an Ex Works basis, with currency options of USD, EUR, or JPY
4. Place your order based on the agreed quotation
5. Receive a Proforma Invoice with payment details; shipment is prepared upon receipt of payment
6. Shipment arranged with full GDP documentation, including cold chain packaging and data logger where required

About TASAKI PHARMA

TASAKI PHARMA is a Taiwan-based pharmaceutical trading company specialising in the international export of Japanese-origin pharmaceutical products. Operating under GDP and PIC/S GMP-compliant procedures, TASAKI PHARMA serves healthcare institutions in Asia-Pacific, Europe, the Middle East, and Oceania.

Current export destinations include Australia, Hong Kong, Singapore, and the United Kingdom, with the capability to supply to any market with an established pharmaceutical importation framework.

For product enquiries, visit tasakipharma.com or search the J-Lex database at db.tasakipharma.com.